Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 285

1.

β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.

Satow R, Shitashige M, Jigami T, Fukami K, Honda K, Kitabayashi I, Yamada T.

Gastroenterology. 2012 Mar;142(3):572-81. doi: 10.1053/j.gastro.2011.11.041. Epub 2011 Dec 9.

PMID:
22155184
2.

In situ SUMOylation analysis reveals a modulatory role of RanBP2 in the nuclear rim and PML bodies.

Saitoh N, Uchimura Y, Tachibana T, Sugahara S, Saitoh H, Nakao M.

Exp Cell Res. 2006 May 1;312(8):1418-30.

PMID:
16688858
3.

ITF2 prevents activation of the β-catenin-TCF4 complex in colon cancer cells and levels decrease with tumor progression.

Shin HW, Choi H, So D, Kim YI, Cho K, Chung HJ, Lee KH, Chun YS, Cho CH, Kang GH, Kim WH, Park JW.

Gastroenterology. 2014 Aug;147(2):430-442.e8. doi: 10.1053/j.gastro.2014.04.047. Epub 2014 May 15.

PMID:
24846398
4.

Regulation of Wnt signaling by the nuclear pore complex.

Shitashige M, Satow R, Honda K, Ono M, Hirohashi S, Yamada T.

Gastroenterology. 2008 Jun;134(7):1961-71, 1971.e1-4. doi: 10.1053/j.gastro.2008.03.010. Epub 2008 Mar 10.

PMID:
18439914
5.

PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence.

Ivanschitz L, Takahashi Y, Jollivet F, Ayrault O, Le Bras M, de Thé H.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14278-83. doi: 10.1073/pnas.1507540112. Epub 2015 Nov 2.

6.

Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells.

Herzer K, Weyer S, Krammer PH, Galle PR, Hofmann TG.

Cancer Res. 2005 Dec 1;65(23):10830-7.

7.

AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.

Li Q, He Y, Wei L, Wu X, Wu D, Lin S, Wang Z, Ye Z, Lin SC.

Oncogene. 2011 Mar 10;30(10):1194-204. doi: 10.1038/onc.2010.499. Epub 2010 Nov 8.

PMID:
21057547
8.

Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.

Percherancier Y, Germain-Desprez D, Galisson F, Mascle XH, Dianoux L, Estephan P, Chelbi-Alix MK, Aubry M.

J Biol Chem. 2009 Jun 12;284(24):16595-608. doi: 10.1074/jbc.M109.006387. Epub 2009 Apr 20.

9.

OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.

Ye GD, Sun GB, Jiao P, Chen C, Liu QF, Huang XL, Zhang R, Cai WY, Li SN, Wu JF, Liu YJ, Wu RS, Xie YY, Chan EC, Liou YC, Li BA.

Gastroenterology. 2016 Mar;150(3):659-671.e16. doi: 10.1053/j.gastro.2015.11.041. Epub 2015 Nov 24.

PMID:
26619963
10.

PML isoforms IV and V contribute to adenovirus-mediated oncogenic transformation by functionally inhibiting the tumor-suppressor p53.

Wimmer P, Berscheminski J, Blanchette P, Groitl P, Branton PE, Hay RT, Dobner T, Schreiner S.

Oncogene. 2016 Jan 7;35(1):69-82. doi: 10.1038/onc.2015.63. Epub 2015 Mar 16.

PMID:
25772236
11.

Oxidative stress-induced assembly of PML nuclear bodies controls sumoylation of partner proteins.

Sahin U, Ferhi O, Jeanne M, Benhenda S, Berthier C, Jollivet F, Niwa-Kawakita M, Faklaris O, Setterblad N, de Thé H, Lallemand-Breitenbach V.

J Cell Biol. 2014 Mar 17;204(6):931-45. doi: 10.1083/jcb.201305148.

12.

Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation.

Gao C, Ho CC, Reineke E, Lam M, Cheng X, Stanya KJ, Liu Y, Chakraborty S, Shih HM, Kao HY.

Mol Cell Biol. 2008 Sep;28(18):5658-67. doi: 10.1128/MCB.00874-08. Epub 2008 Jul 14.

13.

Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells.

Konsavage WM Jr, Kyler SL, Rennoll SA, Jin G, Yochum GS.

J Biol Chem. 2012 Apr 6;287(15):11730-9. doi: 10.1074/jbc.M111.327767. Epub 2012 Feb 15.

14.

The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.

Rabellino A, Carter B, Konstantinidou G, Wu SY, Rimessi A, Byers LA, Heymach JV, Girard L, Chiang CM, Teruya-Feldstein J, Scaglioni PP.

Cancer Res. 2012 May 1;72(9):2275-84. doi: 10.1158/0008-5472.CAN-11-3159. Epub 2012 Mar 9.

15.

Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53.

Sung KS, Lee YA, Kim ET, Lee SR, Ahn JH, Choi CY.

Exp Cell Res. 2011 Apr 15;317(7):1060-70. doi: 10.1016/j.yexcr.2010.12.016. Epub 2010 Dec 28.

PMID:
21192925
16.

Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.

Liu JH, Liu CC, Yen CC, Gau JP, Wang WS, Tzeng CH.

Int J Cancer. 2009 Jul 1;125(1):71-7. doi: 10.1002/ijc.24329.

17.

PML positively regulates interferon gamma signaling.

El Bougrini J, Dianoux L, Chelbi-Alix MK.

Biochimie. 2011 Mar;93(3):389-98. doi: 10.1016/j.biochi.2010.11.005. Epub 2010 Nov 27.

PMID:
21115099
18.

Sumoylation of the Tumor Suppressor Promyelocytic Leukemia Protein Regulates Arsenic Trioxide-Induced Collagen Synthesis in Osteoblasts.

Xu WX, Liu SZ, Wu D, Qiao GF, Yan J.

Cell Physiol Biochem. 2015;37(4):1581-91. doi: 10.1159/000438525. Epub 2015 Nov 2.

19.

Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.

Maroui MA, Kheddache-Atmane S, El Asmi F, Dianoux L, Aubry M, Chelbi-Alix MK.

PLoS One. 2012;7(9):e44949. doi: 10.1371/journal.pone.0044949. Epub 2012 Sep 18.

20.

SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome.

Cao X, Clavijo C, Li X, Lin HH, Chen Y, Shih HM, Ann DK.

Mol Cancer Ther. 2008 Apr;7(4):923-34. doi: 10.1158/1535-7163.MCT-07-0540.

Supplemental Content

Support Center